Retatrutide is an peptide drug developed by Eli Lilly, currently in clinical trials as a next-generation obesity and metabolic treatment. It functions as a triple agonist, simultaneously targeting the GLP-1 (glucagon-like peptide-1), GIP (glucose-dependent insulinotropic polypeptide), and glucagon receptors — making it one of the most advanced peptides in the field of metabolic regulation and weight management.

By activating all three pathways, Retatrutide has demonstrated unprecedented fat loss, improved glucose metabolism, and potential enhancements in energy expenditure. In early clinical trials, it has shown greater weight loss than semaglutide (Ozempic/Wegovy) or tirzepatide (Mounjaro/Zepbound).

Bacteriostatic Water is a sterile, non-pyrogenic solution of water containing 0.9% benzyl alcohol (as a preservative), designed specifically for use in reconstituting lyophilized (freeze-dried) compounds such as peptides, human growth hormone (HGH), and other biologicals.

Its primary purpose is to safely dissolve these powders into an injectable liquid form, allowing for accurate dosing and extended shelf life. The presence of benzyl alcohol inhibits bacterial growth, making BAC Water ideal for multi-dose

COMING SOON!!! NEW PRODUCTS PLUS DIFFERENT SIZE VIAL OPTIONS ON RETATRUTIDE